This is a routine equity grant with no immediate trading signal. The vesting milestones are set far above current market cap ($4M vs $30M+), making near-term dilution unlikely. Monitor for any subsequent 8-Ks that might indicate a reverse stock split or capital raise, which would be necessary to approach those milestones.
Price Chart
Executive Summary
Revelation Biosciences granted restricted stock awards to CEO James Rolke (208,076 shares) and CFO Chester Zygmont (208,073 shares) under the 2021 Equity Incentive Plan. The awards vest in four tranches tied to market capitalization milestones ($30M, $60M, $90M, $120M) or time-based cliffs (2-4 years). This is a routine compensatory arrangement with no departure or appointment of officers — neutral for the stock.
Key Facts
- CEO James Rolke received a Restricted Stock Award covering 208,076 shares.
- CFO Chester S. Zygmont III received a Restricted Stock Award covering 208,073 shares.
- Awards vest in four equal 25% tranches based on market cap milestones ($30M, $60M, $90M, $120M) or time-based cliffs (2-4 years).
- Current market cap is approximately $4M, far below the first $30M vesting milestone.
- No officer departures or appointments were reported — this is a routine equity grant.
Financial Impact
No immediate cash impact; potential dilution of up to 416,149 shares upon full vesting, representing a significant percentage of current shares outstanding given the $4M market cap.
Risk Factors
- Potential dilution of up to 416,149 shares if all tranches vest.
- Market cap milestones ($30M-$120M) are 7.5x to 30x current market cap, suggesting vesting is unlikely without a transformative event or reverse split.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-357120 |
| Document: 0001193125-26-357120-index.html | 0001193125-26-357120 |
| Document: 0001193125-26-357120.txt | 0001193125-26-357120 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 8-K | $1.07 $0.9304 | ▼ −13.05% | ▼ −12.93% | $0.7636 (−28.64%) |
Jun 24, 2026 14w ago | 8-K | $0.9600 $1.07 | ▲ +11.46% | ▲ +10.93% | $0.7636 (−20.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access